CoLucid Pharmaceuticals Inc. (CLCD) CEO Thomas P. Mathers Sells 1,502 Shares
CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) CEO Thomas P. Mathers sold 1,502 shares of the stock in a transaction that occurred on Wednesday, October 5th. The shares were sold at an average price of $37.08, for a total value of $55,694.16. Following the completion of the sale, the chief executive officer now directly owns 248,169 shares of the company’s stock, valued at $9,202,106.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Shares of CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD) traded up 1.034% during midday trading on Friday, hitting $36.635. The company had a trading volume of 73,217 shares. The company’s market cap is $561.76 million. The stock’s 50-day moving average price is $22.84 and its 200-day moving average price is $11.23. CoLucid Pharmaceuticals Inc. has a 12 month low of $3.60 and a 12 month high of $39.27.
CoLucid Pharmaceuticals (NASDAQ:CLCD) last posted its quarterly earnings data on Wednesday, August 10th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by $0.22. On average, equities research analysts forecast that CoLucid Pharmaceuticals Inc. will post ($3.91) EPS for the current year.
A number of large investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in CoLucid Pharmaceuticals by 1.2% in the second quarter. Vanguard Group Inc. now owns 76,242 shares of the biopharmaceutical company’s stock valued at $623,000 after buying an additional 900 shares in the last quarter. Societe Generale acquired a new stake in CoLucid Pharmaceuticals during the second quarter valued at about $464,000. Finally, FMR LLC acquired a new stake in CoLucid Pharmaceuticals during the second quarter valued at about $554,000. Institutional investors own 30.47% of the company’s stock.
Several equities research analysts have recently weighed in on the company. Piper Jaffray Cos. set a $49.00 price objective on CoLucid Pharmaceuticals and gave the company an “overweight” rating in a report on Friday, September 30th. Ladenburg Thalmann set a $57.00 price objective on CoLucid Pharmaceuticals and gave the company a “buy” rating in a report on Monday, September 19th. Stifel Nicolaus increased their price objective on CoLucid Pharmaceuticals from $27.00 to $30.00 and gave the company a “buy” rating in a report on Monday, September 19th. Finally, Zacks Investment Research downgraded CoLucid Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 9th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. CoLucid Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $33.05.
CoLucid Pharmaceuticals Company Profile
CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.
Receive News & Ratings for CoLucid Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CoLucid Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.